Schwab Charles Investment Management Inc. increased its position in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 5.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 79,580 shares of the biotechnology company’s stock after buying an additional 4,446 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.27% of Atara Biotherapeutics worth $1,636,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in ATRA. American International Group Inc. boosted its stake in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Atara Biotherapeutics during the first quarter worth approximately $132,000. Vident Investment Advisory LLC boosted its stake in shares of Atara Biotherapeutics by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 55,665 shares of the biotechnology company’s stock worth $1,144,000 after buying an additional 9,276 shares during the period. Swiss National Bank boosted its stake in shares of Atara Biotherapeutics by 9.6% in the first quarter. Swiss National Bank now owns 28,600 shares of the biotechnology company’s stock worth $588,000 after buying an additional 2,500 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Atara Biotherapeutics by 9.0% in the first quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock worth $1,197,000 after buying an additional 4,791 shares during the period. 78.21% of the stock is owned by institutional investors.
Atara Biotherapeutics, Inc. (ATRA) traded up 0.36% during mid-day trading on Friday, reaching $13.85. The company had a trading volume of 98,634 shares. The firm’s market capitalization is $423.24 million. The firm’s 50-day moving average is $14.82 and its 200-day moving average is $15.90. Atara Biotherapeutics, Inc. has a one year low of $11.80 and a one year high of $23.00.
Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.05. On average, equities research analysts anticipate that Atara Biotherapeutics, Inc. will post ($3.89) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/27/atara-biotherapeutics-inc-atra-position-boosted-by-schwab-charles-investment-management-inc.html.
ATRA has been the subject of a number of recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Canaccord Genuity set a $47.00 price target on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Monday, August 7th. Finally, ValuEngine cut Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Four equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Atara Biotherapeutics presently has an average rating of “Hold” and an average target price of $23.60.
In other news, CEO Isaac E. Ciechanover sold 4,400 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $13.54, for a total value of $59,576.00. Following the completion of the transaction, the chief executive officer now owns 737,767 shares in the company, valued at approximately $9,989,365.18. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $16.94, for a total value of $47,432.00. Following the completion of the transaction, the chief executive officer now owns 731,859 shares of the company’s stock, valued at approximately $12,397,691.46. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,459 shares of company stock valued at $811,787. 16.10% of the stock is currently owned by company insiders.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA).
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
